Posted by Michael Wonder on 19 Sep 2017
FDA grants “fast track” status to Cancer Prevention Pharmaceuticals’ lead drug CPP-1X/sul for treatment of familial adenomatous polyposis
18 September 2017 - CPP-1X/sul aims to prevent disease progression in patients with familial adenomatous polyposis.
Cancer Prevention Pharmaceuticals announced today that the U.S. FDA has granted “fast-track” status for its lead drug CPP-1X/sul for adults with familial adenomatous polyposis (FAP), which is currently in a Phase 3 clinical trial.
FAP is a rare genetic disease that if left untreated progresses to colorectal cancer in nearly 100% of patients. Currently there is no effective treatment for FAP.
